Medical Oncology and Tumor Pharmacotherapy

, Volume 8, Issue 4, pp 265–269 | Cite as

Efficacy of peptide bound m-l-sarcolysin (peptichemio) on melphalan resistant human myeloma cellsIn vitro

  • Rolf Lewensohn
  • Jan-Olof Fernberg
  • Hans Ehrsson
  • Giampaolo Merlini


Peptichemio (PTC) is a mixture of six synthetic oligopeptides, each containing the alkylating agent m-di(2-chloroethyl) amino-phenylalanine. Freshly obtained myeloma cell infiltrated human bone marrow specimens were in parallel exposed to melphalan and PTC. The cytotoxic effect of the drugs on the myeloma cells of each specimen was measured by the differential staining culture method (DISC). PTC displayed higher cytotoxicity to the myeloma cells as compared to melphalan in all 12 cases analysed. The increase of the cytotoxic effect of PTC compared to melphalan varied between different cases. In melphalan resistant cases the cytotoxic effect of PTC as compared to melphalan was clearly significant(P = 0.001).

Key words

Human myeloma cells Melphalan Peptichemio Dye exclusion assay 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    De Barbieri A: Peptichemio: a synthesis of pharmacological, biochemical, and biomolecular investigation, in:Proceedings of the Symposium on Peptichemio, Milan,18, 13 (1972).Google Scholar
  2. 2.
    Zaniboni A, Simoncini E, Marpicati P, Montini E, Rossi G, Marini G: Peptichemio, teniposide and high- dose dexamethasone: a new active combination for relapsing and refractory multiple myeloma. A pilot study.Inticancer Res 8, 125 (1988).Google Scholar
  3. 3.
    Paccagnella A, Salvagno L, Chiarion-Sileni V, Bolzonella S, De Besi P, Frizzarin M, Pappagallo G L, Fosser V P, Formasiero A, Segati R, Fiorentino M V: Peptichemio in pretreated patients with plasma cell neoplasms.Eur Cancer clin Oncol 22, 1053 (1986).CrossRefGoogle Scholar
  4. 4.
    Lewensohn R, Ehrsson H, Hansson J, Ringborg U: Increased toxicity and DNA cross-linking by peptide bound m-L-sarcolvsin (peptichemio) as compared to melphalan and m-L-sarcolysin in human melanoma cells.Anticancer Res 11, 321 (1991).PubMedGoogle Scholar
  5. 5.
    Weisenthal L M, Marsden J A, Dill P L, Macaluso C K: A novel dye exclusion method for testingin vitro chemosensitivity of human tumors.Cancer Res 43, 749 (1983).PubMedGoogle Scholar
  6. 6.
    Einhorn S, Fernberg J-O, Grandér D, Lewensohn R: Interferon exerts a cytotoxic effect on primary human myeloma cells.Eur J Cancer clin Oncol 24, 1505 (1988).PubMedCrossRefGoogle Scholar
  7. 7.
    Böyum A Y: Separation of leukocytes from blood and bone marrow.Scand J clin Lab Invest 21, 1 (1968).CrossRefGoogle Scholar
  8. 8.
    Carella A M, Bacigalupo A, Santini G, Giordano D, Damasio E E, Fusco F A, Marmont A M: Peptichemio; a new oncolytic drug in combination with vincristine and prednisolone in the treatment of non- Hodgkin lymphomas.Acta Hematol (Basel) 57, 211 (1977).Google Scholar
  9. 9.
    De Bernardi B, Comelli A, Cozutto A, Lamedica G, Mori P G, Massimo L: Peptichemio in advanced neuroblastoma.Cancer Treat Rep 62, 811 (1978).Google Scholar
  10. 10.
    Hug V, Hortobagyi G N, Buzdar A U, Blumenschein G R, Grose W, Burgess M A, Bodey G P: A phase II study of peptichemio in advanced breast cancer.Cancer 45, 2524 (1980).PubMedCrossRefGoogle Scholar
  11. 11.
    Merlini G, Gobbi G P, Riccardi A, Riva G, Sardi C, Perugini S: Peptichemio induction therapy in myelomatosis.Cancer Chemother Pharmac 8, 9 (1982).CrossRefGoogle Scholar
  12. 12.
    Paccagnella A, Tredese F, Salvagno L, Brandes A, Sileni V C, Daniele O, Fornasiero A, Fosser V, Nicoletto O, Maggino T: Peptichemio in pretreated patients with ovarian cancer.Cancer Treat Rep 69, 17 (1985).PubMedGoogle Scholar
  13. 13.
    Bird M C. Bosanquet A G, Gilby E D:In vitro determination of tumour chemosensitivity in hematological malignancies.Hematol Oncol 3, 1 (1985).PubMedCrossRefGoogle Scholar
  14. 14.
    Weisenthal L M, Dill P L, Finkelstein J Z, Duarte T E, Baker J A, Moran E M: Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasms.Cancer Treat Rep 70, 1283 (1986).PubMedGoogle Scholar
  15. 15.
    Yagi M J, Scanlon K J, Holland J M, Bekesi J G: Cellular transport of PTT. 119. A new chemother- apeutic agent transported by multiple amino acid carrier systems.Proceedings of the American Association of Cancer Res 27, Abstr. 1070 (1986).Google Scholar
  16. 16.
    Batist G, Torres-Garcia S, Demuys J-M, Greene D, Lehnert S, Rochon M, Panasci L: Enhanced DNA cross-link removal: the apparent mechanism of resistance in a clinically relevant melphalan-resistant human breast cancer cell line.Mol Pharmacol 36, 224 (1989).PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 1991

Authors and Affiliations

  • Rolf Lewensohn
    • 1
  • Jan-Olof Fernberg
    • 1
  • Hans Ehrsson
    • 2
  • Giampaolo Merlini
    • 3
  1. 1.RadiumhemmetKarolinska HospitalStockholmSweden
  2. 2.Karolinska PharmacyStockholmSweden
  3. 3.Dipartimento di Medicina Interna e Terapia MedicaUniversita di PaviaPaviaItaly

Personalised recommendations